Nexpring Health

Nexpring Health provides critical consumables and advanced equipment for in-vitro fertilization (IVF) procedures. Its portfolio integrates solutions for micromanipulation, vitrification, and embryo culture media, supporting clinics and laboratories globally. The company focuses on high-quality, innovative products to advance reproductive science.

Formed in 2024, Nexpring Health strategically consolidated key players in reproductive health. This began with the carve-out of Cook Medical's Reproductive Health portfolio and the take-private of Hamilton Thorne Ltd. The underlying insight was unifying established expertise, leading to the acquisition of Irvine Scientific’s Reproductive Health assets in early 2025 for a comprehensive platform.

Nexpring Health serves thousands of hospitals, specialized clinics, and IVF laboratories across over 115 countries. Its mission centers on improving outcomes and increasing global accessibility for fertility treatments. Leveraging its strengths, the company aims to advance reproductive medicine and support individuals toward parenthood.